Company description

Catalyst Pharmaceuticals, Inc. (ticker CPRX) is a specialty biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare diseases. The company is dedicated to providing life-changing treatments for patients suffering from debilitating neurological and neuromuscular disorders. CPRX has a diverse portfolio of development programs targeting rare diseases, including its most advanced product, Firdapse, which has been approved by the FDA for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). The company also has multiple ongoing clinical trials for potential treatments for other rare diseases such as MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy type 3 (SMA-3). CPRX's strong financial position and partnerships with leading healthcare organizations have allowed them to further advance their research and development efforts. With a mission to improve the lives of patients with rare diseases, CPRX continues to make significant strides in the biopharmaceutical industry.